Otoacoustic Emissions in Different Blood Types

Completed

• Conditions: Hearing Loss, Cochlear
• Interventions: Diagnostic Test: Otoacoustic emissions (non-invasive)

• Registration Number: NCT06326866
• Lead Sponsor: Istanbul University - Cerrahpasa (IUC)

Brief Summary

The objective of this study is to examine whether ABO and Rhesus (Rh) blood group systems have an association with distortion product otoacoustic emission (DPOAE) and transient otoacoustic emission (TEOAE) amplitudes with the hypothesis of blood groups may affect hearing thresholds.

Detailed Description

Many factors have a significant impact on otoacoustic emission (OAE) measurement and quality of analysis. Race, age and gender are among the non-pathological factors. To date there is clear data to demonstrate the association of blood types with OAEs. The aim of our research is to investigate the relation of different blood groups (ABO) and Rh factors on transient evoked OAE and distortion product OAE amplitudes and inner ear potentials, differences between ears and to contribute to the limited literature on cochlear hearing loss susceptibility and blood groups with the hypothesis that blood groups may be associated with hearing thresholds.

Study Timeline

• Study Start: 2024-02-07
• Status Verified: 2024-03
• Primary Completion: 2024-03-12
• Study Completion: 2024-03-18
• Study First Submitted: 2024-03-18
• Study First Submitted QC: 2024-03-18
• Study First Posted: 2024-03-22
• Last Update Submitted: 2024-03-23
• Last Update Posted: 2024-03-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• not having hearing loss
• having a blood group card obtained from health institutions

Exclusion Criteria

• not meeting inclusion criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Individuals with B Rh (-) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as B Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with A Rh (+) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as A Rh (+) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with O Rh (+) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as O Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with O Rh (-) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as O Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with A Rh (-) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as A Rh (-) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with B Rh (+) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as B Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with AB Rh (+) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as AB Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Individuals with AB Rh (-) blood group	Otoacoustic emissions (non-invasive)	Individuals with normal hearing and whose blood group was previously determined as AB Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.

Primary Outcome Measures

Name	Time	Method
Signal to noise ratios	1 month	SNRs obtained for different frequencies in OAE In TEOAE, 1, 1.4, 2, 2.8, 4 kHz, in DPOAE 1, 1.4, 2, 2.8, 4, 6 kHz

Trial Locations

Locations (1)

Eyyup KARA; 🇹🇷 İstanbul, Turkey